Open AccessCirculating Tumor Cells: Triple Selection Strategy for In Situ Labeling of Circulating Tumor Cells with High Purity and Viability toward Preclinical Personalized Drug Sensitivity Analysis (Adv. Biosys. 6/2020)
Author(s) -
Mu HsuanYo,
Ou YenChuan,
Chuang HanNi,
Lu TsaiJung,
Jhan PeiPei,
Hsiao TzuHung,
Huang JenHuang
Publication year - 2020
Publication title -
advanced biosystems
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.153
H-Index - 18
ISSN - 2366-7478
DOI - 10.1002/adbi.202070063
Subject(s) - circulating tumor cell , prostate cancer , microfluidic chip , cancer research , in situ , tumor cells , medicine , cancer , oncology , microfluidics , chemistry , metastasis , materials science , nanotechnology , organic chemistry
In article number 2000013, Tzu‐Hung Hsiao, Jen‐Huang Huang, and co‐workers present a strategy to retrieve viable circulating tumor cells (CTCs) with high purity from blood in patients with prostate cancer and obtain the survival rate of the CTCs after one day of in situ drug treatment on a separated microfluidic chip. Cover art prepared by Yu‐Lun Lu.